Lecia V Sequist, MD MPH

Trials

Studies that name Lecia V Sequist, MD MPH as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:42 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03778229 · Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

  AstraZeneca · active not recruiting · Carcinoma · principal investigator
• Ph2
  NCT01553942 · Afatinib With CT and RT for EGFR-Mutant NSCLC

  Massachusetts General Hospital · active not recruiting · Lung Cancer · principal investigator
• Ph2
  NCT01228435 · IPI-504 in NSCLC Patients With ALK Translocations

  Massachusetts General Hospital · terminated · Lung Cancer, Stage IIIb Lung Cancer, Stage IV Lung Cancer · principal investigator
• N/A
  NCT01061944 · Biopsies of Cancer Patients for Tumor Molecular Characterization

  Massachusetts General Hospital · completed · Cancer, Metastatic Cancer · principal investigator
• Ph2
  NCT00567359 · Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

  Massachusetts General Hospital · completed · Non-small Cell Lung Cancer · principal investigator
• Ph2
  NCT00411047 · Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

  Massachusetts General Hospital · completed · Lung Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.